We are pleased to announce the new dates and location for the Trans-Pacific Health Sciences Dialogue 2015:
October 14-15, 2015
The Joseph B. Martin Conference Center at Harvard Medical School, Boston, MA
More information coming soon.
Take a look at some photos from the 2014 Trans-Pacific Health Sciences Dialogue!
About the Conference
The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.
Industry News from BioCentury
- Tricida raises $30M series BRenal company Tricida Inc. (South San Francisco, Calif.) raised a $30 million series B round led by existing investor OrbiMed. Existing investors Sibling Capital Ventures and Limulus Venture Partners also participated.
Tricida hopes to submit an IND this year for lead compound TRC101, which it is developing to treat electrolyte imbalances in chronic kidney disease patients.
Industry News from PharmAsia
- Turkey Regulatory Update: SGK Resignation, Drug ShortagesThe president of the SGK has resigned her post to run in coming parliamentary elections, although the reimbursement body has added 105 new medicines to its list. Meanwhile, low prices continue to negatively affect access to medicines, a Chinese company could not pass Turkish quality standards, and a new tender for hepatitis A vaccines will be concluded shortly.<img src="//feeds.feedburner.com/~r/_PharmAsiaNews/~4/nJLlJA8zyTw" height="1" width="1" alt="" />